Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

With JBCHEPHARM's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 4.921000
forwardPE 30.459726
debtToEquity 0.086000
earningsGrowth -0.310000
revenueGrowth -0.048000
grossMargins 0.677670
operatingMargins 0.164760
trailingEps 44.430000
forwardEps 73.014440

JBCHEPHARM's current ratio of 4.921 highlights the company's ability to easily cover its short-term debt using its available cash and assets. This indicates a strong liquidity position, ensuring JBCHEPHARM is unlikely to face difficulties in meeting immediate financial obligations.
JBCHEPHARM's low growth in both earnings and revenue indicates the company's profits may decrease. This trend could signal a downturn in financial performance, suggesting that JBCHEPHARM might struggle to maintain its current profit levels.
J. B. Chemicals & Pharmaceuticals Limited's negative gross and operating margins indicate that the company is not generating profit from either production or day-to-day operations. This could suggest cost overruns or declining revenue, impacting its financial stability.
J. B. Chemicals & Pharmaceuticals Limited's forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with J. B. Chemicals & Pharmaceuticals Limited anticipated to deliver better earnings than it did in the prior year.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM

JBCHEPHARM's stock price has consistently been near the lower edge of expected values, indicating potential struggles in meeting growth projections. This trend may reflect a cautious market sentiment toward the company.

Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


46 transactions were made to sell JBCHEPHARM shares, with market price of 1740.13695758322.3 buy transactions of JBCHEPHARM stock were completed, with market price at 1875.4333089192708.There is no discernible trend in insider transactions, making it hard to determine whether these actions signal positive or negative developments within the company.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


J. B. Chemicals & Pharmaceuticals Limited has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view J. B. Chemicals & Pharmaceuticals Limited as a reliable choice for their money, offering a promising avenue for future growth and financial gains.